Development of a transcutaneous vaccination technique for the treatment of malignant diseases

Development of a transcutaneous vaccination technique for the treatment of malignant diseases

Cytotoxic T lymphocytes (CTL) play a fundamental role in the elimination of malignant cells. To do so, they need to be activated by tumor-specific structures in a pro-inflammatory milieu. In fully synthetic vaccines, this is achieved by ligands for toll-like receptors (TLR) in combination with peptide antigens. The aim of this project is the preclinical development of a transcutaneous vaccine for the treatment of tumors. This kind of vaccine is inexpensive to manufacture and safe to use. If proved to be effective, this vaccination method can be universally applied and/or, if the target antigen is known, be customized to tumor or disease entities and rapidly brought to clinical application.